Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217886 · ClinicalTrials.gov registry record · Phase 1
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
A Phase 1 study of Renal Impairment, sponsored by Shionogi.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT07217886: Recruiting Phase 1 study of Renal Impairment, sponsored by Shionogi.
NCT07217886 is a Phase 1 study of Renal Impairment that is actively recruiting participants, run by Shionogi. The registered enrollment target is 40 participants, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (21% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217886, a Phase 1 study of Renal Impairment, is actively recruiting participants, sponsored by Shionogi.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
Conditions Studied
Interventions
- DRUG S-892216-PO
Study Locations (4)
Florida
- Orlando Clicinal Research Center - Orlando
- Global Clinical Professionals (GCP) LLC - St. Petersburg
- Genesis Clinical Research - Tampa
Tennessee
- Alliance for Multispecialty Research (AMR)-Knoxville - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 1 |
What NCT07217886 shows while recruiting
NCT07217886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (21% higher).
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which S-892216-PO is the first listed.
NCT07217886 reports a single indexed study location in Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07217886 about?
NCT07217886 is a clinical study titled "A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls". The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
What is the current status of trial NCT07217886?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-10-16. Estimated completion is 2026-06-05.
What conditions does trial NCT07217886 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT07217886?
The interventions under investigation include: S-892216-PO (DRUG).
Who is sponsoring clinical trial NCT07217886?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217886 being conducted?
This trial has 4 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07217886's enrollment target sits among peer trials
40 9th of 32 higher than 24 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI